PDF(Pubmed)
Abstract：
Pulmonary blastoma (PB) is a rare and invasive malignancy of the lungs with a poor prognosis. Although the mainstay treatment of PB is surgery, and radiotherapy and chemotherapy have been reported, no standard therapy exists for patients inoperable in advanced stages. Moreover, little is known about driver mutation status and immunotherapy efficacy. This paper presents a male patient diagnosed with classic biphasic PB using CT-guided lung biopsy pathology and immunohistochemistry. The patient\'s symptoms included cough, chest pain, shortness of breath, hemoptysis, and hypodynamia. The primary focus of this paper is to discuss the impact of anti-PD-1 immunotherapy on PB. The patient experienced progression-free survival (PFS) of over 27 months following sintilimab second-line anti-PD-1 therapy. The patient has currently survived for nearly 40 months with a satisfactory quality of life.
摘要：
肺母细胞瘤（PB）是一种罕见的侵袭性肺部恶性肿瘤，预后不良。虽然PB的主要治疗方法是手术，放疗和化疗已经有报道，对于晚期不能手术的患者，没有标准的治疗方法。此外，对驱动突变状态和免疫疗法疗效知之甚少。本文介绍了使用CT引导的肺活检病理和免疫组织化学诊断为经典双相PB的男性患者。病人的症状包括咳嗽,胸痛,呼吸急促,咯血,和缺乏活力。本文主要讨论抗PD-1免疫治疗对PB的影响。在sintilimab二线抗PD-1治疗后，患者经历了超过27个月的无进展生存期（PFS）。该患者目前存活了近40个月，生活质量令人满意。
